PSP001 - A First-in-disease human PEGIFN-λ Chimera
| Jan 7th, 2021 FDA IND Submission; |
| Date:2019-08-05 18:47:50 | Visits： |
| Prev:Feb 3rd 2021. FDA issued letter "Safe-to-proceed"; Next:Status：Q4 2019, FDA Pre-IND Meeting; |
| Jan 7th, 2021 FDA IND Submission; |
| Date:2019-08-05 18:47:50 | Visits： |
| Prev:Feb 3rd 2021. FDA issued letter "Safe-to-proceed"; Next:Status：Q4 2019, FDA Pre-IND Meeting; |
Beijing Headquarter:
Add: A302 No.5 Kaituo Road, Haidian District, Beijing, China, 100085
Tel: +86-10-62975234
Manufacturing Facility & Laboratory:
Building No. 3, Peptide Valley, GuAn, Hebei, China
US Clinical Center:
Seattle, WA, USA